Anthony R Mato (Anthony Mato)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 11

Top Topics

Prognostic Factors

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Top Venues

American journal of hematology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Michael L Wang, Wojciech Jurczak, Pier Luigi Luigi Zinzani, Toby Andrew Eyre, Chan Yoon Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian W Flinn, Benoît Tessoulin, Alvaro J Alencar, Shuo Ma, David John Lewis, Ewa Lech-Maranda, Joanna M Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S Tam, Tahla Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S Fenske, John Francis Seymour, Andrew D Zelenetz, Binoj Nair, Donald E Tsai, Minna Balbas, Richard A Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R Mato, Nirav N Shah
Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Scott F Huntington, Stephen J Schuster, Wei Ding, Amber B Koehler, Danielle M Brander, Allison C Rosenthal, Jose F Leis, Han W Tun, Muhamad Alhaj Moustafa, Madiha Iqbal, Wei He, Albert S Kearney, Timothy P McKinlay, Min Gui, Anthony R Mato
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: an open-label, multicenter, phase 1a/1b study. American journal of hematology (2023)
Christine E Ryan, Matthew S Davids, Richard Hermann, Mina Shahkarami, Juliana Biondo, Sarang Abhyankar, Hasan Alhasani, Jeff P Sharman, Anthony R Mato, Lindsey Elizabeth Roeker
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future oncology (London, England) (2022)
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali, Stacey M Fernandes, Alberto J Arribas, Abdul K Hilli, Kjetil Taskén, Francesco Bertoni, Anthony R Mato, Emmanuel Normant, Jennifer R Brown, Geir Erland Tjønnfjord, Tero Aittokallio, Sigrid S Skånland
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (20) (2022)
Julia H Aronson, Sigrid S Skånland, Lindsey E Roeker, Meghan C Thompson, Anthony R Mato
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare). American journal of hematology (2022)
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, Nicole Lamanna, John M Pagel, Ian W Flinn, Jacqueline C Barrientos, Kanti R Rai, James A Reeves, Bruce D Cheson, Paul M Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J Pu, Alan P Skarbnik, Lindsey Roeker, Gustavo A Fonseca, Andrea Sitlinger, Issam S Hamadeh, Colleen Dorsey, Nicole LaRatta, Hanna Weissbrot, Eline T Luning Prak, Patricia Tsao, Dana Paskalis, Peter Sportelli, Hari P Miskin, Michael S Weiss, Jakub Svoboda, Danielle M Brander
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. Blood 137 (20) (2021)
John C Byrd, Peter Hillmen, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil E Kay, Jose A Garcia-Marco, Anthony R Mato, Javier Pinilla-Ibarz, John Francis Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (31) (2021)
Antonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N Allan, John M Pagel, Danielle M Brander, Brian T Hill, Allison M Winter, Nicole Lamanna, Constantine S Tam, Ryan Jacobs, Frederick Lansigan, Paul M Barr, Mazyar Shadman, Alan P Skarbnik, Jeffrey J Pu, Alison R Sehgal, Stephen J Schuster, Nirav N Shah, Chaitra S Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, null null
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer medicine 9 (22) (2020)
Brian Koffman, Anthony R Mato, John C Byrd, Alexey Danilov, Brad Hedrick, Chaitra Ujjani, Lindsey Roeker, Deborah M Stephens, Matthew S Davids, John M Pagel, Mazyar Shadman
Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. American journal of hematology 95 (8) (2020)
Anthony R Mato, Lindsey E Roeker, John N Allan, John M Pagel, Danielle M Brander, Brian T Hill, Bruce D Cheson, Richard R Furman, Nicole Lamanna, Constantine S Tam, Sasanka Handunnetti, Ryan Jacobs, Frederick Lansigan, Erica Bhavsar, Paul M Barr, Mazyar Shadman, Alan P Skarbnik, Andre Goy, Douglas F Beach, Jakub Svoboda, Jeffrey J Pu, Alison R Sehgal, Clive S Zent, Hande H Tuncer, Stephen J Schuster, Peter V Pickens, Nirav N Shah, Joanna Rhodes, Chaitra S Ujjani, Chadi Nabhan
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. American journal of hematology 93 (11) (2018)
Maryam Sarraf Yazdy, Anthony R Mato, Bruce D Cheson
Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)? Blood 133 (2) (2018)